ClinicalTrials.gg
CompletedNCT00438360Updated Aug 9, 2011Results posted

Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis

A Phase 3 interventional study of Cyclosporine A microemulsion and Placebo in Chronic Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-08-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies in Psoriasis by Novartis — 3 open to participants now, 4 under way, none of them phase 3. Psoriasis · Novartis.

Enrollment
18th of 53
243 · median 177
Started
2006
with 1 other
Phase 3
30 of 68
none open now
Registered
3rd of 68
by date

Among the 68 studies in Psoriasis by Novartis, this one is the 18th largest by enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2006, is one of 30 in phase 3, and was the 3rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 68 studies in Psoriasis by Novartis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Psoriasis by Novartis, or all of them as a file.
02

Study summary

The study will evaluate the efficacy of cyclosporine at 2, 5 mg/kg/day bid (i.e. bis in a day), when administered twice a week compared to continuous administration, in patients with chronic plaque psoriasis.

03

Conditions studied

  • Chronic Plaque Psoriasis

Browse trials for

Keywords

  • Cyclosporine, chronic plaque psoriasis, intermittent therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients 18 years of age and older (max 65 years)
  • Patients with chronic plaque psoriasis on disease remission (i.e. PASI ≤75% of PASI before cyclosporine continuous treatment course) entering a maintenance period
  • Disease remission obtained with only cyclosporine as systemic therapy (maximum dose 5 mg/kg/day) for >8 weeks and \<16 weeks
  • PASI still \<75% of PASI before cyclosporine continuous treatment course, at randomization to study treatment (8±2 days after disease remission)

Exclusion criteria

Exclusion criteria:

  • Abnormal renal function (creatinine ≥ 10% the upper limit of the reference range)
  • Severe chronic degenerative diseases
  • Severe uncontrolled hypertension
  • Body weigh >110 kg
  • Abnormal liver function
  • Hyperkalemia or hyperuricemia
  • impairment of hematopoietic and cardiovascular function
  • Concomitant therapy with nephrotoxic medications
  • Patients with or a history of malignancy
  • Females of who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of
  • Clinically significant uncontrolled bacterial, viral or fungal infection
  • Evidence of drug and/or alcohol abuse
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
243 participants (actual)

Study arms

  • Active comparator
    Cyclosporine A

    Oral soft gelatin capsules of cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations

    Drug: Cyclosporine A microemulsion

  • Placebo comparator
    Placebo

    Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations

    Drug: Placebo

Interventions

  • Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations

    Also known as: Neoral

  • DrugPlacebo

    Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations

06

What researchers measure

Primary outcomes

  1. Number of Participants With Relapse Rate (Success or Failure), as Assessed by Psoriasis Area and Severity Index (PASI) Score

    PASI is an index used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (best) to 72 (worst), with the highest score representing complete erythroderma of severest degree. Relapse is considered a worsening of psoriasis associated to a PASI score \>75% of PASI score recorded before starting induction therapy with CsA (before study start). Each patient was considered as failure (relapse occurrence) if rate was \>= 75%. In all the other cases the patient was considered as success (no relapse).

    Time frame: 24 weeks

Secondary outcomes

  1. Proportion of Participants With Clinical Relapse

    Clinical relapse was defined as worsening of psoriasis associated with a Psoriasis Area and Severity Index (PASI) \>75% of the PASI score assessed before the continuous treatment, or when the investigator or the patient judged it necessary to change the treatment.

    Time frame: 24 weeks

  2. Change From Baseline in Psoriasis Area and Severity Index (PASI) Score

    PASI is an index used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (best) to 72 (worst), with the highest score representing complete erythroderma of the severest degree.

    Time frame: baseline and week 24

  3. Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis

    BSA is a measure of the percentage of body surface affected by psoriasis. Using the Mosteller Formula: BSA = BSA (m²) = ( \[Height(in) x Weight(lbs) \]/ 3131 )½ . A covariance analysis was performed on all variables, with value assessed at visit 2 as covariate and center as effect. For each variable the changes versus the last available measures were computed

    Time frame: Baseline and week 24

  4. Change From Baseline in Visual Analogue Scale (VAS) for Patient Self Assessment of Pruritus

    Target lesion pruritus as measured by the Visual Analog Scale (VAS) from 0 to 100 mm at week 24 compared to baseline (with 0 being no pruritis and 100 being maximum pruritis).

    Time frame: Baseline and week 24

  5. Safety / Tolerability Assessed by Adverse Events

    Time frame: 24weeks

07

Results

Posted Aug 9, 2011

Participant flow

Participant flow — Overall Study
MilestoneCyclosporine APlacebo
Started16281
Intention to treat (itt) population16079
Completed9038
Not completed7243
Withdrew: Adverse event61
Withdrew: Lack of efficacy4227
Withdrew: Other2415

Outcome measures

PrimaryNumber of Participants With Relapse Rate (Success or Failure), as Assessed by Psoriasis Area and Severity Index (PASI) Score

PASI is an index used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (best) to 72 (worst), with the highest score representing complete erythroderma of severest degree. Relapse is considered a worsening of psoriasis associated to a PASI score \>75% of PASI score recorded before starting induction therapy with CsA (before study start). Each patient was considered as failure (relapse occurrence) if rate was \>= 75%. In all the other cases the patient was considered as success (no relapse).

Time frame:
24 weeks
Reported as:
Number · Participants
Number of Participants With Relapse Rate (Success or Failure), as Assessed by Psoriasis Area and Severity Index (PASI) Score
ParticipantsCyclosporine APlacebo
Success at 6 months8736
Failure at 6 months7343
SecondaryProportion of Participants With Clinical Relapse

Clinical relapse was defined as worsening of psoriasis associated with a Psoriasis Area and Severity Index (PASI) \>75% of the PASI score assessed before the continuous treatment, or when the investigator or the patient judged it necessary to change the treatment.

Time frame:
24 weeks
Reported as:
Number · proportion of participants
Proportion of Participants With Clinical Relapse
proportion of participantsCyclosporine APlacebo
Proportion of Participants With Clinical Relapse0.3690.456
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Score

PASI is an index used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (best) to 72 (worst), with the highest score representing complete erythroderma of the severest degree.

Time frame:
baseline and week 24
Reported as:
Mean · Units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
Units on a scaleCyclosporine APlacebo
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score5.70 ± 8.06.86 ± 8.4
SecondaryChange From Baseline in Body Surface Area (BSA) Affected by Psoriasis

BSA is a measure of the percentage of body surface affected by psoriasis. Using the Mosteller Formula: BSA = BSA (m²) = ( \[Height(in) x Weight(lbs) \]/ 3131 )½ . A covariance analysis was performed on all variables, with value assessed at visit 2 as covariate and center as effect. For each variable the changes versus the last available measures were computed

Time frame:
Baseline and week 24
Reported as:
Mean · BSA (m^2)
Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis
BSA (m^2)Cyclosporine APlacebo
Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis8.12 ± 12.910.45 ± 16.7
SecondaryChange From Baseline in Visual Analogue Scale (VAS) for Patient Self Assessment of Pruritus

Target lesion pruritus as measured by the Visual Analog Scale (VAS) from 0 to 100 mm at week 24 compared to baseline (with 0 being no pruritis and 100 being maximum pruritis).

Time frame:
Baseline and week 24
Reported as:
Mean · Units on a scale
Change From Baseline in Visual Analogue Scale (VAS) for Patient Self Assessment of Pruritus
Units on a scaleCyclosporine APlacebo
Change From Baseline in Visual Analogue Scale (VAS) for Patient Self Assessment of Pruritus17.32 ± 30.925.44 ± 31.9
SecondarySafety / Tolerability Assessed by Adverse Events
Time frame:
24weeks
Reported as:
Number · patient

Results for this outcome have not been posted.

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cyclosporine A—1/160 (0.6%)19/160 (11.9%)
Placebo—0/79 (0%)1/79 (1.3%)
Most frequent serious events
Most frequent serious events
EventCyclosporine APlacebo
Breast massReproductive system and breast disorders1/1600/79
Most frequent other events
Most frequent other events
EventCyclosporine APlacebo
Abdominal pain upperGastrointestinal disorders12/1601/79
HypertriglyceridaemiaMetabolism and nutrition disorders8/1600/79

Baseline characteristics

Age, Customized
Age, Customized(Participants)Cyclosporine APlaceboTotal
between 18-45 years10048148
Between 46 and 65 years592988
>=65 years123
Sex: Female, Male
Sex: Female, Male(Participants)Cyclosporine APlaceboTotal
Female553287
Male10547152
08

Study locations

1 site
  • Novartis Investigative Site
    Bari, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2007
First posted
Feb 22, 2007
Start
May 2006
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Results first posted
Aug 9, 2011
Last update
Aug 9, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00438360
First posted
Feb 22, 2007
Start date
May 2006
Primary completion
Nov 2007
Completion
Nov 2007
Results posted
Aug 9, 2011
Last update
Aug 9, 2011

Study contacts

Novartis
study director · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion